Patents by Inventor Marilyn H. Perrin

Marilyn H. Perrin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20160375102
    Abstract: A search of the public human genome database identified a human EST, GenBank accession number AW293249, which has high homology to known pufferfish urocortin sequences. The full length sequence was amplified from human genomic DNA and sequenced. Sequence homology comparisons of the novel sequence with human urocortin I and urocortin II revealed that the sequence encoded a novel human urocortin, which was designated urocortin III (UcnIII). While urocortin III does not have high affinity for either CRF-R1 or CRF-R2, the affinity for CRF-R2 is greater than the affinity for CRF-R1. Urocortin III is capable stimulating cyclic AMP production in cells expressing CRF-R2? or ?. Thus, the affinity is high enough that urocortin III could act as a native agonist of CRF-R2. However, it is also likely that urocortin III is a stronger agonist of a yet to b e identified receptor.
    Type: Application
    Filed: July 8, 2016
    Publication date: December 29, 2016
    Applicant: Research Development Foundation
    Inventors: Wylie W. VALE, JR., Kathy A. LEWIS, Marilyn H. PERRIN, Koichi KUNITAKE, Jean E. F. RIVIER, Jozsef GULYAS
  • Patent number: 9388229
    Abstract: A search of the public human genome database identified a human EST, GenBank accession number AW293249, which has high homology to known pufferfish urocortin sequences. The full length sequence was amplified from human genomic DNA and sequenced. Sequence homology comparisons of the novel sequence with human urocortin I and urocortin II revealed that the sequence encoded a novel human urocortin, which was designated urocortin III (UcnIII). While urocortin III does not have high affinity for either CRF-R1 or CRF-R2, the affinity for CRF-R2 is greater than the affinity for CRF-R1. Urocortin III is capable stimulating cyclic AMP production in cells expressing CRF-R2? or ?. Thus, the affinity is high enough that urocortin III could act as a native agonist of CRF-R2. However, it is also likely that urocortin III is a stronger agonist of a yet to be identified receptor.
    Type: Grant
    Filed: February 12, 2014
    Date of Patent: July 12, 2016
    Assignee: Research Development Foundation
    Inventors: Wylie W. Vale, Jr., Kathy A. Lewis, Marilyn H. Perrin, Koichi Kunitake, Jean E. F. Rivier, Jozsef Gulyas
  • Publication number: 20140288161
    Abstract: A search of the public human genome database identified a human EST, GenBank accession number AW293249, which has high homology to known pufferfish urocortin sequences. The full length sequence was amplified from human genomic DNA and sequenced. Sequence homology comparisons of the novel sequence with human urocortin I and urocortin II revealed that the sequence encoded a novel human urocortin, which was designated urocortin III (UcnIII). While urocortin III does not have high affinity for either CRF-R1 or CRF-R2, the affinity for CRF-R2 is greater than the affinity for CRF-R1. Urocortin III is capable stimulating cyclic AMP production in cells expressing CRF-R2? or ?. Thus, the affinity is high enough that urocortin III could act as a native agonist of CRF-R2. However, it is also likely that urocortin III is a stronger agonist of a yet to be identified receptor.
    Type: Application
    Filed: February 12, 2014
    Publication date: September 25, 2014
    Applicant: RESEARCH DEVELOPMENT FOUNDATION
    Inventors: Wylie W. VALE, JR., Kathy A. LEWIS, Marilyn H. PERRIN, Koichi KUNITAKE, Jean E. F. RIVIER, Jozsef GULYAS
  • Patent number: 8669092
    Abstract: A search of the public human genome database identified a human EST, GenBank accession number AW293249, which has high homology to known pufferfish urocortin sequences. The full length sequence was amplified from human genomic DNA and sequenced. Sequence homology comparisons of the novel sequence with human urocortin I and urocortin II revealed that the sequence encoded a novel human urocortin, which was designated urocortin III (UcnIII). While urocortin III does not have high affinity for either CRF-R1 or CRF-R2, the affinity for CRF-R2 is greater than the affinity for CRF-R1. Urocortin III is capable stimulating cyclic AMP production in cells expressing CRF-R2? or ?. Thus, the affinity is high enough that urocortin III could act as a native agonist of CRF-R2. However, it is also likely that urocortin III is a stronger agonist of a yet to be identified receptor.
    Type: Grant
    Filed: May 1, 2013
    Date of Patent: March 11, 2014
    Assignee: Rsearch Development Foundation
    Inventors: Wylie W. Vale, Jr., Kathy A. Lewis, Marilyn H. Perrin, Koichi Kunitake, Jean E. F. Rivier, Jozsef Gulyas
  • Publication number: 20140004603
    Abstract: A search of the public human genome database identified a human EST, GenBank accession number AW293249, which has high homology to known pufferfish urocortin sequences. The full length sequence was amplified from human genomic DNA and sequenced. Sequence homology comparisons of the novel sequence with human urocortin I and urocortin II revealed that the sequence encoded a novel human urocortin, which was designated urocortin III (UcnIII). While urocortin III does not have high affinity for either CRF-R1 or CRF-R2, the affinity for CRF-R2 is greater than the affinity for CRF-R1. Urocortin III is capable stimulating cyclic AMP production in cells expressing CRF-R2? or ?. Thus, the affinity is high enough that urocortin III could act as a native agonist of CRF-R2. However, it is also likely that urocortin III is a stronger agonist of a yet to be identified receptor.
    Type: Application
    Filed: May 1, 2013
    Publication date: January 2, 2014
    Applicant: Research Development Foundation
    Inventors: Wylie W. VALE, JR., Kathy A. LEWIS, Marilyn H. PERRIN, Koichi KUNITAKE, Jean E. F. RIVIER, Jozsef GULYAS
  • Patent number: 8445425
    Abstract: A search of the public human genome database identified a human EST, GenBank accession number AW293249, which has high homology to known pufferfish urocortin sequences. The full length sequence was amplified from human genomic DNA and sequenced. Sequence homology comparisons of the novel sequence with human urocortin I and urocortin II revealed that the sequence encoded a novel human urocortin, which was designated urocortin III (UcnIII). While urocortin III does not have high affinity for either CRF-R1 or CRF-R2, the affinity for CRF-R2 is greater than the affinity for CRF-R1. Urocortin III is capable stimulating cyclic AMP production in cells expressing CRF-R2? or ?. Thus, the affinity is high enough that urocortin III could act as a native agonist of CRF-R2. However, it is also likely that urocortin III is a stronger agonist of a yet to be identified receptor.
    Type: Grant
    Filed: December 16, 2011
    Date of Patent: May 21, 2013
    Assignee: Research Development Foundation
    Inventors: Wylie W. Vale, Jr., Kathy A. Lewis, Marilyn H. Perrin, Koichi S. Kunitake, Jean E. Rivier, Jozsef Gulyas
  • Publication number: 20120270792
    Abstract: A search of the public human genome database identified a human EST, GenBank accession number AW293249, which has high homology to known pufferfish urocortin sequences. The full length sequence was amplified from human genomic DNA and sequenced. Sequence homology comparisons of the novel sequence with human urocortin I and urocortin II revealed that the sequence encoded a novel human urocortin, which was designated urocortin III (UcnIII). While urocortin III does not have high affinity for either CRF-R1 or CRF-R2, the affinity for CRF-R2 is greater than the affinity for CRF-R1. Urocortin III is capable stimulating cyclic AMP production in cells expressing CRF-R2? or ?. Thus, the affinity is high enough that urocortin III could act as a native agonist of CRF-R2. However, it is also likely that urocortin III is a stronger agonist of a yet to be identified receptor.
    Type: Application
    Filed: December 16, 2011
    Publication date: October 25, 2012
    Inventors: Wylie W. Vale, JR., Kathy A. Lewis, Marilyn H. Perrin, Koichi S. Kunitake, Jean E. Rivier, Jozsef Gulyas
  • Patent number: 8084413
    Abstract: A search of the public human genome database identified a human EST, GenBank accession number AW293249, which has high homology to known pufferfish urocortin sequences. The full length sequence was amplified from human genomic DNA and sequenced. Sequence homology comparisons of the novel sequence with human urocortin I and urocortin II revealed that the sequence encoded a novel human urocortin, which was designated urocortin III (UcnIII). While urocortin III does not have high affinity for either CRF-R1 or CRF-R2, the affinity for CRF-R2 is greater than the affinity for CRF-R1. Urocortin III is capable stimulating cyclic AMP production in cells expressing CRF-R2? or ?. Thus, the affinity is high enough that urocortin III could act as a native agonist of CRF-R2. However, it is also likely that urocortin III is a stronger agonist of a yet to be identified receptor.
    Type: Grant
    Filed: November 6, 2008
    Date of Patent: December 27, 2011
    Assignee: Research Development Foundation
    Inventors: Wylie W. Vale, Jr., Kathy A. Lewis, Marilyn H. Perrin, Koichi S. Kunitake, Jean E. Rivier, Jozsef Gulyas
  • Patent number: 8044025
    Abstract: A human urocortin-related peptide with significant sequence homology to the CRF neuropeptide family was identified. A mouse cDNA was isolated from whole brain poly (A+) RNA that encodes a predicted 38 amino acid peptide protein designated herein as urocortin II. Both human URP and mouse Ucn II are structurally related to the other known mammalian family members, CRF and urocortin (Ucn). These peptides are involved in the regulation of the hypothalamic-pituitary-adrenal axis under basal and stress conditions, suggesting a similar role for URP and Ucn IL Synthesized Ucn-II and URP peptide binds with higher affinity to CRF-R2 than to CRF-R1 Ucn II and human URP appear to be involved in the regulation of body temperature and appetite and may play a role in other stress related phenomenon. These findings identify Ucn II and human URP as a new members of the CRF family of neuropeptides, which are expressed centrally and bind to CRF-R2.
    Type: Grant
    Filed: December 7, 2009
    Date of Patent: October 25, 2011
    Assignee: Research Development Foundation
    Inventors: Wylie W. Vale, Jr., Teresa M. Reyes, Paul E. Sawchenko, Jean E. Rivier, Kathy A. Lewis, John B. Hogenesch, Joan M. Vaughan, Marilyn H. Perrin
  • Patent number: 7869958
    Abstract: The present invention relates to a method for identifying modulators of B1 G-protein coupled receptors. The present invention also relates to a method for identifying an antagonist or agonist of the corticotropin-releasing factor receptor 2 (CRFR2). The present invention also relates to a method for improving antagonists or agonists of CRFR2. The present invention also relates to the three-dimensional structure of CRFR2 as representative of the B1 GPCR subfamily and its use as a basis for rational drug design of antagonist or agonists of B1 GPCRs.
    Type: Grant
    Filed: August 9, 2005
    Date of Patent: January 11, 2011
    Assignee: Research Development Foundation
    Inventors: Grace Christy Rani Royappa, Marilyn H. Perrin, Jean E. Rivier, Wylie W. Vale, Jr., Roland Riek
  • Patent number: 7851588
    Abstract: CRF peptide analogs that bind to CRFR1 with an affinity far greater than they bind to CRFR2. Some of these analogs exhibit CRF agonist activity. One exemplary analog that may be made by solid-phase synthesis is: (cyclo 31-34)[Ac-Pro4,D-Phe12,Nle18,21,Glu31,Lys34]-sucker urotensin(4-41).
    Type: Grant
    Filed: February 6, 2009
    Date of Patent: December 14, 2010
    Assignee: The Salk Institute for Biological Studies
    Inventors: Jean E. F. Rivier, Wylie W. Vale, Jr., Marilyn H. Perrin, Jozsef Gulyas
  • Publication number: 20100168021
    Abstract: A human urocortin-related peptide with significant sequence homology to the CRF neuropeptide family was identified. A mouse cDNA was isolated from whole brain poly (A+) RNA that encodes a predicted 38 amino acid peptide protein designated herein as urocortin II. Both human URP and mouse Ucn II are structurally related to the other known mammalian family members, CRF and urocortin (Ucn). These peptides are involved in the regulation of the hypothalamic-pituitary-adrenal axis under basal and stress conditions, suggesting a similar role for URP and Ucn IL Synthesized Ucn-II and URP peptide binds with higher affinity to CRF-R2 than to CRF-R1 Ucn II and human URP appear to be involved in the regulation of body temperature and appetite and may play a role in other stress related phenomenon. These findings identify Ucn II and human URP as a new members of the CRF family of neuropeptides, which are expressed centrally and bind to CRF-R2.
    Type: Application
    Filed: December 7, 2009
    Publication date: July 1, 2010
    Applicant: RESEARCH DEVELOPMENT FOUNDATION
    Inventors: Wylie Walker Vale, JR., Teresa M. Reyes, Paul E. Sawchenko, Jean E. Rivier, Kathy A. Lewis, John B. Hogenesch, Joan M. Vaughan, Marilyn H. Perrin
  • Patent number: 7638607
    Abstract: A human urocortin-related peptide with significant sequence homology to the CRF neuropeptide family was identified. A mouse CDNA was isolated from whole brain poly (A+) RNA that encodes a predicted 38 amino acid peptide protein designated herein as urocortin II. Both human URP and mouse Ucn II are structurally related to the other known mammalian family members, CRF and urocortin (Ucn). These peptides are involved in the regulation of the hypothalamic-pituitary-adrenal axis under basal and stress conditions, suggesting a similar role for URP and Ucn IL Synthesized Ucn-II and URP peptide binds with higher affinity to CRF-R2 than to CRF-R1 Ucn II and human URP appear to be involved in the regulation of body temperature and appetite and may play a role in other stress related phenomenon. These findings identify Ucn II and human URP as a new members of the CRF family of neuropeptides, which are expressed centrally and bind to CRF-R2.
    Type: Grant
    Filed: April 5, 2007
    Date of Patent: December 29, 2009
    Assignee: Research Development Foundation
    Inventors: Wylie Walker Vale, Jr., Teresa M Reyes, Paul E Sawchenko, Jean E F Rivier, Kathy A Lewis, John B Hogenesch, Joan M Vaughan, Marilyn H Perrin
  • Publication number: 20090156493
    Abstract: A search of the public human genome database identified a human EST, GenBank accession number AW293249, which has high homology to known pufferfish urocortin sequences. The full length sequence was amplified from human genomic DNA and sequenced. Sequence homology comparisons of the novel sequence with human urocortin I and urocortin II revealed that the sequence encoded a novel human urocortin, which was designated urocortin III (UcnIII). While urocortin III does not have high affinity for either CRF-R1 or CRF-R2, the affinity for CRF-R2 is greater than the affinity for CRF-R1. Urocortin III is capable stimulating cyclic AMP production in cells expressing CRF-R2? or ?. Thus, the affinity is high enough that urocortin III could act as a native agonist of CRF-R2. However, it is also likely that urocortin III is a stronger agonist of a yet to be identified receptor.
    Type: Application
    Filed: November 6, 2008
    Publication date: June 18, 2009
    Inventors: Wylie W. Vale, JR., Kathy A. Lewis, Marilyn H. Perrin, Koichi S. Kunitake, Jean E. Rivier, Jozsef Gulyas
  • Publication number: 20090149629
    Abstract: CRF peptide analogs that bind to CRFR1 with an affinity far greater than they bind to CRFR2. Some of these analogs exhibit CRF agonist activity. One exemplary analog that may be made by solid-phase synthesis is: (cyclo 31-34)[Ac-Pro4, D-Phe12, Nle18,21, Glu31, Lys34]-sucker urotensin(4-41).
    Type: Application
    Filed: February 6, 2009
    Publication date: June 11, 2009
    Applicant: The Salk Institute for Biological Studies
    Inventors: Jean E.F. Rivier, Wylie W. Vale, JR., Marilyn H. Perrin, Jozsef Gulyas
  • Patent number: 7498300
    Abstract: CRF peptide analogs that bind to CRFR1 with an affinity far greater than they bind to CRFR2. These analogs exhibit CRF agonist activity. One exemplary analog that may be made by solid-phase synthesis is (cyclo 31-34)[Ac-Pro4, D-Phe12, Nle21,38, Glu31, Lys34]-r/hCRF(4-41).
    Type: Grant
    Filed: January 22, 2004
    Date of Patent: March 3, 2009
    Assignee: The Salk Institute for Biological Studies
    Inventors: Jean E. F. Rivier, Wyle W. Vale, Jr., Marilyn H. Perrin, Jozsef Gulyas
  • Patent number: 7459427
    Abstract: A search of the public human genome database identified a human EST, GenBank accession number AW293249, which has high homology to known pufferfish urocortin sequences. The full length sequence was amplified from human genomic DNA and sequenced. Sequence homology comparisons of the novel sequence with human urocortin I and urocortin II revealed that the sequence encoded a novel human urocortin, which was designated urocortin III (UcnIII). While urocortin III does not have high affinity for either CRF-R1 or CRF-R2, the affinity for CRF-R2 is greater than the affinity for CRF-R1. Urocortin III is capable stimulating cyclic AMP production in cells expressing CRF-R2? or ?. Thus, the affinity is high enough that urocortin III could act as a native agonist of CRF-R2. However, it is also likely that urocortin III is a stronger agonist of a yet to be identified receptor.
    Type: Grant
    Filed: August 29, 2005
    Date of Patent: December 2, 2008
    Assignee: Research Development Foundation
    Inventors: Wylie W. Vale, Jr., Kathy A. Lewis, Marilyn H. Perrin, Koichi S. Kunitake, Jean E. Rivier, Jozsef Gulyas
  • Patent number: 7358225
    Abstract: In accordance with the present invention, there are provided novel G-protein-coupled receptor proteins (CRF-R) characterized by having sufficient binding affinity for corticotropin releasing factor (CRF) such that concentrations of £ 10 nM of CRF occupy 350% of the binding sites of said receptor protein. Nucleic acid sequences encoding such receptors, assays employing same, as well as antibodies derived therefrom, are also disclosed. Invention CRF-Rs can be employed in a variety of ways, such as, for example, in bioassays, for production of antibodies thereto, in therapeutic compositions containing such proteins and/or antibodies.
    Type: Grant
    Filed: August 26, 2003
    Date of Patent: April 15, 2008
    Assignee: The Salk Institute for Biological Studies
    Inventors: Marilyn H. Perrin, Ruoping Chen, Kathy A. Lewis, Wylie W. Vale, Jr., Cynthia J. Donaldson, Paul Sawchenko
  • Patent number: 7223846
    Abstract: A human urocortin-related peptide with significant sequence homology to the CRF neuropeptide family was identified. A mouse cDNA was isolated from whole brain poly (A+) RNA that encodes a predicted 38 amino acid peptide protein designated herein as urocortin II. Both human URP and mouse Ucn II are structurally related to the other known mammalian family members, CRF and urocortin (Ucn). These peptides are involved in the regulation of the hypothalamic-pituitary-adrenal axis under basal and stress conditions, suggesting a similar role for URP and Ucn II. Synthesized Ucn-II and URP peptide binds with higher affinity to CRF-R2 than to CRF-R1 Ucn II and human URP appear to be involved in the regulation of body temperature and appetite and may play a role in other stress related phenomenon. These findings identify Ucn II and human URP as a new members of the CRF family of neuropeptides, which are expressed centrally and bind to CRF-R2.
    Type: Grant
    Filed: October 25, 2004
    Date of Patent: May 29, 2007
    Assignee: Research Development Foundation
    Inventors: Wylie Walker Vale, Jr., Teresa M Reyes, Paul E Sawchenko, Jean E F Rivier, Kathy A Lewis, John B Hogenesch, Joan M Vaughan, Marilyn H Perrin
  • Patent number: 7141546
    Abstract: CRF peptide analogs that bind to CRFR2 with an affinity far greater than they bind to CRFR1. These analogs exhibit CRF antagonist activity, and they can be based upon the native structures of sauvagine, CRF, and urocortin.
    Type: Grant
    Filed: July 31, 2002
    Date of Patent: November 28, 2006
    Assignee: The Salk Institute for Biologicial Studies
    Inventors: Jean E. F. Rivier, Wylie W. Vale, Marilyn H. Perrin, Jozsef Gulyas, Dean A. Kirby